Management of the Axilla in Early-Stage Breast Cancer

Publication Date: July 19, 2021
Last Updated: September 2, 2022


I. Staging

For patients ≥70 years of age with clinically node-negative (T1N0) early-stage invasive breast cancer that is hormone receptor positive and HER2 negative, sentinel lymph node bioposy (SLNB) is NOT required.

( IC , Ins , B , M )

This is supported by the Choosing Wisely statement released on July 12, 2016, and updated on June 20, 2019 by the Society of Surgical Oncology (SSO) available at: that stated: “Don’t routinely use sentinel node biopsy in clinically node negative women ≥70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer” if they will be treated with hormonal therapy. If omission of SLNB is considered, a consultation with a medical oncologist can be considered before surgery to discuss hormonal therapy.




Management of the Axilla in Early-Stage Breast Cancer

Authoring Organizations